Shares of LifeStance Health Group, Inc. (LFST) surged 5.33% in pre-market trading on Thursday, following the company's impressive fourth-quarter results and positive outlook for 2025, along with the announcement of a leadership transition.

For the fourth quarter of 2024, LifeStance reported a narrower net loss of $7.1 million compared to a loss of $45 million in the prior-year period. Adjusted EBITDA stood at $32.8 million, surpassing analysts' estimates of $23.2 million. Notably, the company's revenue climbed 16% year-over-year to $325.5 million, beating the consensus estimate of $313.72 million.

Looking ahead, LifeStance provided an upbeat revenue forecast for 2025, projecting revenue in the range of $1.40 billion to $1.44 billion. This outlook exceeded analysts' expectations of $1.38 billion, fueling investor optimism about the company's growth trajectory.

Additionally, LifeStance announced a leadership transition, appointing Dave Bourdon as the company's new Chief Executive Officer, effective March 3. Bourdon, who joined LifeStance as Chief Financial Officer in 2022, will succeed Ken Burdick, who will assume the role of Executive Chairman. This move is seen as a strategic step to further strengthen the company's position in the mental health care industry.